Spurned by AstraZeneca, is Pfizer out for GlaxoSmithKline?

The latest market chatter is that Pfizer ($PFE), rebuffed in its quest to acquire AstraZeneca ($AZN) last year, is taking a hard look at GlaxoSmithKline ($GSK), and one analyst says it might be a good idea. As Bloomberg notes, Deutsche Bank's Gregg Gilbert wrote in a note to investors that buying GlaxoSmithKline could solve some of Pfizer's tax woes by giving it a U.K. address, pointing to "a sense of urgency to create value by leveraging the power of its balance sheet to do needle-moving deals." Story | More from FiercePharma